secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001193125-26-133363
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio secures $75M non-dilutive RIPA financing; $25M note conversion reduces debt
--------------------------------------------------------------------------------

- Additional $75M under Revenue Interest Purchase Agreement (RIPA) with Oberland Capital; total committed capital $375M.
- Royalty payback rate increased to tiered 5.625%-12.5% of net sales; cap at 195% of cumulative payments.
- Proceeds to support global expansion, pipeline advancement, and general corporate purposes.
- Nant Capital converted $25M of convertible note into 4,606,596 shares; note outstanding now $480M.
- Recent ANKTIVA approvals in US, UK, EU, Saudi Arabia, Macau; covering ~34 countries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000119312526133363/0001193125-26-133363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000119312526133363/d139829d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-133363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer